Does the PSA test for prostate cancer save lives? New data reverse gold-standard findings

A recent Cochrane review has reversed its previous stance on prostate-cancer screening with the PSA blood test, now suggesting it likely reduces the risk of dying from prostate cancer without increasing negative side effects. This change is based on data from nearly 800,000 people, including two new trials and additional years of data from older studies. Although the number of lives saved is small, this finding could influence global screening guidelines. The PSA test, developed in the 1980s, detects prostate cancer but can also flag non-threatening conditions, leading to unnecessary treatments. Past trials in the US and Europe showed mixed results, contributing to ongoing debate about the test’s benefits. This new review may impact future screening policies and practices. QUESTION: How might changing guidelines for PSA testing influence the way people approach their health and medical decisions?